D-0086-2026 Class II Ongoing
FDA drug recall D-0086-2026 was initiated by GenoGenix LLC on Jul 30, 2025 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is ongoing.
Recall details
- Product Type
- Drugs
- Report Date
- Oct 15, 2025
- Initiation Date
- Jul 30, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
Product description
BPC-157/Thymosin Beta-4 for Injection, a) 10/10mg, b) 15/15mg, c) 15mg/15mg, all presentations, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692. Also labeled as manufactured for CELIA Health, Extension Health and Medical Health Institute (MHI).
Reason for recall
Lack of Assurance of Sterility
Distribution pattern
US Nationwide.
Code information
Lot#: GG020525-001, GG060525-001, GG062625-004, within expiry.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0086-2026
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026